Written by: L Madeline McCraryHideji FujiwaraJohn RobinsonJeannie KellyMegan R CurtisMichael J DurkinTracey Habrock-BachJeffrey P HendersonLaura R Marks
Find these authors on Roon
MM
Dr. Madeline McCrary
General ID · WUSTL
JK
Dr. Jeannie Kelly
MFM · WUSTL
Summary
In this prospective pharmacokinetic study of women undergoing chronic hepatitis C virus treatment with glecaprevir/pibrentasvir, the mean glecaprevir and pibrentasvir concentrations in breastmilk were 0.63% and 4.23% of maternal plasma concentrations, with a mean relative infant dose of 0.02% and 0.06%, respectively.
JK
Dr. Jeannie Kelly
Obstetrics & Gynecology (OBGYN) · Maternal Fetal Medicine (MFM)Washington University in St. LouisdrjeanniekellySt. Louis, MO